Celia Goeldner, PhD
Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Switzerland
Original Research
Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia
April 15, 2026
Although basmisanil did not improve cognitive deficits, the results offer insight into factors that should facilitate design of more informative trials.
